Loading...
The New England Journal of Medicine has published results of six industry-sponsored randomized trials covering two new all-oral treatment regimens for chronic hepatitis C virus (HCV) genotype 1 infections.
In three studies, about 2000 patients received various durations of the oral drug combination sofosbuvir (Sovaldi) plus ledipasvir, given once daily. Sustained viral response rates were consistently in the 94% to 99% range with 8-week or 12-week treatment courses, both among previously untreated patients and among nonresponders to previous interferon-based regimens. Most of these patients did not have cirrhosis; however, among those with cirrhosis who had not responded to previous therapy, responses approached 100% when treatment was exten…